Hodgkin lymphoma
A study of low-dose nivolumab with standard chemotherapy in patients with advanced Hodgkin lymphoma who do not show a good early response to treatment
Who can joinChildren and adults
Age15–60 years
Kind of studyPhase 2: does it work?
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
Tata Memorial HospitalMumbaiDirections ↗
Registry summary (technical)
Low Dose Nivolumab and AVD in Interim PET-2 Positive Advanced Hodgkin Lymphoma (LD40 Study) - NIL
Sponsor: Tata Memorial Centre
CTRI/2026/04/109059 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 27 Apr 2026 · read by us 5 Nov 2026